

[← News & updates](#)

NBCD Working Group ends 2020 with presence at two nanomedicine events

[News](#) | 6 January 2021

To round off a year of successful engagement despite the restrictions on face-to-face meetings, the NBCD Working Group (WG) took part in two important nanomedicine events towards the end of 2020.

The first was the [EAASM meeting](#), held on 30 November. The event brought together members of the European Parliament, experts from the European Commission, as well as patient representatives, regulatory agency delegates, and other interested parties. Following a [previous meeting](#) co-hosted by EAASM in 2019, this session discussed how an appropriate science-based regulatory approval process would look for nanomedicines and their follow-on versions. Jon de Vlieger, NBCD WG Coordinator, presented the NBCD WG views on the topic. The meeting concluded that with the EU Pharma strategy being detailed and updates to legislation to come, now is the time to make sure we establish a fit for purpose framework for nanomedicines and their follow-on versions.

The second event was an [expert meeting](#) on NBCDs hosted by the Regulatory Science Network Netherlands (RSNN) on 8 December. During an interactive and inspiring session, a total of 14 participants actively discussed the challenges of regulating NBCDs in the EU. The event brought together a nice mix of participants including regulators, clinical experts, industry partners and academics. The results of the session will soon be shared in a formal report.

Share this page... [f](#) [in](#) [X](#) [✉](#)